This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity

Myeloproliferative Neoplasms

SGI-110

Weill Cornell Medical College

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Complete remission rate is defined as number of subjects with complete remission according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Hematological response is defined as number of subjects with hematological response according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Spleen response rate is defined as improvement in size of spleen as measured by US/CT scan and according to the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Symptom improvement response is defined as number of subjects with improvement in symptoms response as defined by Myelofibrosis Symptom Assessment Form (MF-SAF)

Weill Medical College of Cornell University

Astex Pharmaceuticals, Inc.

Breast Cancer

Bone Metastasis

Pain

chemoradiation

Rabin Medical Center, Beilinson Campus

Chemoradiation for Bone Metastasis

Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis

Patients were asked to score their pain on a scale of 0 (no pain) to 10 (worst possible pain) before treatment and at 1, 2, 4, 8 and 12 weeks after treatment initiation.

Consumption of analgesics was evaluated by the physician using the 5-point WHO score, as follows: level 0, no analgesics required; level 1, non-narcotic analgesics required occasionally; level 2, non-narcotic analgesics required regularly; level 3, narcotic analgesics required occasionally; level 4, narcotic analgesics required regularly

Rabin Medical Center

Sheba Medical Center

erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)

Non-small Cell Lung Cancer

Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.

erlotinib in combination with capecitabine

Cancer Center of Sun Yat-Sen University (CCSU)

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

the percentage of patients who got a complete response, partial response and stable disease at week 12 and at week 18

cytidine/kuhara

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Chemoradiation for Bone Metastasis

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi